Literature DB >> 16304179

In vivo measurement of levofloxacin penetration into lung tissue after cardiac surgery.

Doris Hutschala1, Keso Skhirtladze, Andreas Zuckermann, Wilfried Wisser, Peter Jaksch, Bernhard Xaver Mayer-Helm, Heinz Burgmann, Ernst Wolner, Markus Müller, Edda M Tschernko.   

Abstract

Nosocomial pneumonia is a severe complication after cardiac surgery (CS). Levofloxacin, a fluoroquinolone, qualifies for the therapy of postoperative pneumonia. However, penetration properties of levofloxacin into the lung tissue could be substantially affected by CS: atelectasis, low cardiac output after CS, high volume loads, and inflammatory capillary leak potentially influence drug distribution. The aim of our study was to gain information on interstitial antibiotic concentrations in lung tissue in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. Therefore, six patients undergoing elective CS participated in this prospective study. A dose of 500 mg of levofloxacin was administered intravenously in addition to standard antibiotic prophylaxis immediately after the end of surgery. Time versus concentration profiles of levofloxacin in the interstitial lung tissue and plasma were determined. A microdialysis technique was used for lung interstitial concentration measurements. The microdialysis procedure was well tolerated in all patients and no adverse events were observed. The median area under the concentration curve (AUC) of levofloxacin in interstitial lung fluid was 18.6 microg.h/ml (range, 10.1 to 33.6). The median AUC for tissue (AUC(tissue)) of unbound levofloxacin/AUC(total) in plasma was 0.6 (range, 0.4 to 0.9). The median unbound AUC(tissue)/MIC was 2.4 (range, 1.3 to 4.2) for Pseudomonas aeruginosa. Our study demonstrated the feasibility and safety of microdialysis in human lung tissue in vivo after CS. The unbound AUC/MIC ratio revealed that levofloxacin used in the described manner was borderline sufficient for the treatment of nosocomial pneumonia caused by Klebsiella pneumoniae and insufficient for the treatment of pneumonia caused by Pseudomonas aeruginosa, because the breakpoint of 30 to 40 for AUC/MIC could not be reached by the conventionally used dosage schema in our post-CS setting. Penetration was lower than in previous reports.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16304179      PMCID: PMC1315976          DOI: 10.1128/AAC.49.12.5107-5111.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis.

Authors:  M A Zeitlinger; P Dehghanyar; B X Mayer; B S Schenk; U Neckel; G Heinz; A Georgopoulos; M Müller; C Joukhadar
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

2.  Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings.

Authors:  Gary J Noel; Daniel B Goodman; Shuchean Chien; Bhavna Solanki; Mukund Padmanabhan; Jaya Natarajan
Journal:  J Clin Pharmacol       Date:  2004-05       Impact factor: 3.126

3.  The antimicrobial activity of cefpirome, a new cephalosporin.

Authors:  R Wise; J M Andrews; C Cross; L J Piddock
Journal:  J Antimicrob Chemother       Date:  1985-04       Impact factor: 5.790

Review 4.  Nosocomial pneumonia. Diagnostic and therapeutic considerations.

Authors:  B A Cunha
Journal:  Med Clin North Am       Date:  2001-01       Impact factor: 5.456

Review 5.  Microdialysis. A novel tool for clinical studies of anti-infective agents.

Authors:  C Joukhadar; H Derendorf; M Müller
Journal:  Eur J Clin Pharmacol       Date:  2001-06       Impact factor: 2.953

Review 6.  Mediastinitis after cardiac surgery--epidemiology and current treatment.

Authors:  G Marggraf; F H Splittgerber; M Knox; J C Reidemeister
Journal:  Eur J Surg Suppl       Date:  1999

7.  A prospective study of wound infection in coronary artery surgery.

Authors:  J Bellchambers; J M Harris; P Cullinan; H Gaya; J R Pepper
Journal:  Eur J Cardiothorac Surg       Date:  1999-01       Impact factor: 4.191

Review 8.  A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.

Authors:  S J Martin; R Jung; C G Garvin
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

9.  Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults.

Authors:  Blair Capitano; Holly M Mattoes; Eric Shore; Aidan O'Brien; Sidney Braman; Chistina Sutherland; David P Nicolau
Journal:  Chest       Date:  2004-03       Impact factor: 9.410

10.  Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae.

Authors:  Naomi R Florea; Pamela R Tessier; Cuilian Zhang; Charles H Nightingale; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

View more
  11 in total

1.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

Review 2.  Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents.

Authors:  Daniel Gonzalez; Stephan Schmidt; Hartmut Derendorf
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

3.  Simultaneous Semimechanistic Population Analyses of Levofloxacin in Plasma, Lung, and Prostate To Describe the Influence of Efflux Transporters on Drug Distribution following Intravenous and Intratracheal Administration.

Authors:  Estevan Sonego Zimmermann; João Victor Laureano; Camila Neris Dos Santos; Stephan Schmidt; Chakradhar V Lagishetty; Whocely Victor de Castro; Teresa Dalla Costa
Journal:  Antimicrob Agents Chemother       Date:  2015-11-30       Impact factor: 5.191

Review 4.  Use of pharmacodynamic principles to optimise dosage regimens for antibacterial agents in the elderly.

Authors:  Ayman M Noreddin; Virginia Haynes
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

5.  Population pharmacokinetic modeling of the unbound levofloxacin concentrations in rat plasma and prostate tissue measured by microdialysis.

Authors:  Felipe K Hurtado; Benjamin Weber; Hartmut Derendorf; Guenther Hochhaus; Teresa Dalla Costa
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

6.  The impact of perioperative atelectasis on antibiotic penetration into lung tissue: an in vivo microdialysis study.

Authors:  Doris Hutschala; Christian Kinstner; Keso Skhirtladze; Bernhard-Xaver Mayer-Helm; Markus Zeitlinger; Wilfried Wisser; Markus Müller; Edda Tschernko
Journal:  Intensive Care Med       Date:  2008-05-14       Impact factor: 17.440

7.  Lung microdialysis study of levofloxacin in rats following intravenous infusion at steady state.

Authors:  Sandrine Marchand; Denis Frasca; Claire Dahyot-Fizelier; Céline Breheret; Olivier Mimoz; William Couet
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

8.  Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients.

Authors:  Thomas Horvatits; Reinhard Kitzberger; Andreas Drolz; Christian Zauner; Walter Jäger; Michaela Böhmdorfer; Stefanie Kraff; Achim Fritsch; Florian Thalhammer; Valentin Fuhrmann; Peter Schenk
Journal:  Antimicrob Agents Chemother       Date:  2013-10-21       Impact factor: 5.191

9.  Time-kill effect of levofloxacin on multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: synergism with imipenem and colistin.

Authors:  A Safarika; I Galani; A Pistiki; E J Giamarellos-Bourboulis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-09-06       Impact factor: 3.267

10.  Levofloxacin cures experimental pneumonic plague in African green monkeys.

Authors:  Robert Colby Layton; William Mega; Jacob D McDonald; Trevor L Brasel; Edward B Barr; Andrew P Gigliotti; Frederick Koster
Journal:  PLoS Negl Trop Dis       Date:  2011-02-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.